Protective effect of adenylate deaminase (from Penicillium lanoso-viride) against acute infections in mice

• Published in: Immunopharmacology Vol. 35; no. 2; pp. 163 - 169
• Main Authors: Nikolajeva, Vizma, Eze, Daina, Kamradze, Antra, Indulena, Muza, Muiznieks, Indrikis
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.1996
• Subjects: Acute Disease; Adenylate deaminase; AMP Deaminase - biosynthesis; AMP Deaminase - therapeutic use; Animals; Female; Immunomodulation; Infections; Influenza A virus - drug effects; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Orthomyxoviridae Infections - drug therapy; Orthomyxoviridae Infections - prevention & control; Penicillium - metabolism; Pseudomonas Infections - drug therapy; Pseudomonas Infections - prevention & control; Salmonella Infections, Animal - drug therapy; Salmonella Infections, Animal - prevention & control; Salmonella typhimurium - drug effects; Immunomodulation; Adenylate deaminase; Infections
• ISSN: 0162-3109
• DOI: 10.1016/S0162-3109(96)00142-7

We examined the effects of the immunomodulator-adenylate deaminase (E.C. 3.5.4.6) from Penicillium lanoso-viride on experimental mice infections. Prophylactic intraperitoneal administration of adenylate deaminase (ADA) increased survival time and numbers of survivors after infection with Salmonella typhimurium, Pseudomonas aeruginosa and influenza A (H3N2) virus. Protection against influenza virus after intranasal ADA application was also observed. The influence of ADA was time and dose dependent. The most pronounced protection was obtained by administration of 3 U ADA/mice 24 h prior to infection. ADA had no antibiotic effect against these bacterial strains. Protective effects of ADA were studied in immunosuppressed mice under different regimes of treatment including cyclosporin A and trypan blue. The results indicated, that the protective effect of ADA is of a complex nature and probably depends on both T-cell and macrophage components.